The CEO provided updates on CX-801 and CX-2051 studies, targeting CRC. CX-801 plans to start KEYTRUDA combo by 2025, while CX-2051 expects therapeutic range from dose level 3, aiming for success in late-line CRC with RECIST responses.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay